Edgewise Therapeutics (EWTX) stock price is $46.05, down 5.52% on the day, as of Nov 10, 2026. It has a market cap of $5.00Bn and a P/E ratio of 4.96, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap5.00 Bn
P/E4.96
FCF (Yr)-144.07 Mn
ROA (Yr)-32.29
EV to EBIT-10.25
Net Income (Yr)-167.80 Mn
Enterprise Value2.24 Bn
Add ratio to table…
About
Edgewise Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing small molecule therapies for serious muscle diseases, including neuromuscular and cardiac conditions. The company leverages a proprietary muscle focused drug discovery platform that combines deep expertise in muscle biology with high throughput whole muscle assays to identify precision medicines that regulate key sarcomere proteins. Its pipeline includes clinical stage…
Edgewise Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing small molecule therapies for serious muscle diseases, including neuromuscular and cardiac conditions. The company leverages a proprietary muscle focused drug discovery platform that combines deep expertise in muscle biology with high throughput whole muscle assays to identify precision medicines that regulate key sarcomere proteins. Its pipeline includes clinical stage candidates for Duchenne and Becker muscular dystrophy, hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction, with sevasemten as the most advanced candidate being an orally administered allosteric selective fast myofiber myosin inhibitor designed to reduce contraction induced injury in dystrophinopathies. Additional programs include EDG-7500, a novel oral cardiac sarcomere modulator under investigation for obstructive and non obstructive hypertrophic cardiomyopathy, and EDG-15400, which is being studied for heart failure with preserved ejection fraction. The company has retained global development and commercialization rights to all of its programs.
Edgewise Therapeutics, Inc. does not yet generate revenue from product sales because its therapeutic candidates remain in preclinical or clinical development. The company has not received approval for any of its drug candidates, and therefore does not record sales revenue from marketed products. Financial support is derived primarily from public and private equity offerings, as well as occasional collaboration agreements that provide funding for research and development activities. No product royalties or licensing income are reported at this stage of the company’s growth.
Edgewise Therapeutics, Inc. occupies a niche within the biopharmaceutical industry as a specialist in muscle targeted small molecules, competing with larger firms such as Sarepta Therapeutics, Pfizer, and Bristol Myers Squibb that also pursue treatments for muscular dystrophy and cardiac diseases. In the Duchenne and Becker space, the company faces competition from exon skipping therapies marketed by Sarepta Therapeutics and Nippon Shinyaku, glucocorticoid therapies such as deflazacort and prednisone, and emerging gene therapy approaches from companies like Solid Biosciences and Sarepta. For hypertrophic cardiomyopathy, competitors include Bristol Myers Squibb with its cardiac myosin inhibitor mavacamten and Cytokinetics with aficamten, as well as off label use of beta blockers and calcium channel blockers. Edgewise’s competitive advantage stems from its proprietary discovery platform, which enables the design of highly selective molecules that modulate specific sarcomere proteins without broadly suppressing muscle function, offering a potential differentiation from non selective therapies. The oral administration of its candidates and their mechanism aimed at reducing contraction induced injury while preserving systolic function further distinguish the company’s approach from existing intravenous or non selective treatments.
Edgewise Therapeutics, Inc. serves patients suffering from rare muscle disorders, including those with Duchenne and Becker muscular dystrophy, obstructive and non obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction. The company’s clinical trials enroll participants through hospitals, academic medical centers, and patient advocacy groups in the United States, Europe, and other regions, though it does not disclose specific hospital or clinic names in its filings. As its therapies remain investigational, the current customer base consists of trial investigators, study coordinators, and the patients receiving investigational doses, with no commercial customers or prescription sales reported to date.
Sector:HealthcareSector rationaleEdgewise Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapies for muscle diseases, such as Duchenne muscular dystrophy and hypertrophic cardiomyopathy. Its core activity is the development of pharmaceutical candidates (e.g., sevasemten, EDG-7500) through clinical trials, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:PharmaceuticalsPharmaceuticalsPrimaryEdgewise Therapeutics focuses on discovering and developing small molecule therapies, such as sevasemten and EDG-7500, for muscle diseases. Because its pipeline consists of small-molecule drug candidates rather than biologics, it fits the Pharmaceuticals classification.Classified using BQ-MICSCIK: 0001710072
Bull & bear
Investment Thesis
▲ Bull case
Edgewise Therapeutics is positioned for transformative value creation through the Servier transaction, which provides $1.55 billion in upfront cash, significantly de-risking the company's near-term operations while unlocking its cardiovascular pipeline. This transaction eliminates the financial burden of muscular dystrophy program development, allowing Edgewise to redirect capital and focus entirely toward EDG-7500 for hypertrophic cardiomyopathy (HCM) and EDG-15400 for heart failure with preserved ejection fraction (HFpEF). With $1.55 billion in upfront proceeds combined with its existing cash balance of approximately $500 million as of Q1 2026, Edgewise now holds over $2 billion in liquidity, which management explicitly states will fully fund EDG-7500 development through potential approval. This financial strength removes a critical overhang that has historically weighed on biotech valuations—particularly the need for dilutive financing—while enabling aggressive investment in Phase 3 trials without compromise. The market may be underestimating how this structural shift transforms Edgewise from a dual-program clinical-stage company with high cash burn into a pure-play cardiovascular innovator with fortress-like balance sheet strength, potentially attracting a premium valuation multiple as investors re-rate the company on its de-risked, focused pipeline.
The near-term catalysts for EDG-7500 in HCM are substantially derisked by compelling interim safety and efficacy data, with the CIRRUS-HCM Part D 12-week readout expected in Q2 2026 poised to confirm a best-in-class profile. Unlike cardiac myosin inhibitors (CMIs), which carry inherent risks of systolic dysfunction and heart failure due to their mechanism of action, EDG-7500 has consistently demonstrated no clinically meaningful reductions in left ventricular ejection fraction (LVEF) or events of LVEF falling below 50% across all trial phases, including Part D interim safety updates. This differentiated safety profile—preserving systolic function while improving diastolic markers like NT-proBNP, KCCQ scores, and LVOT gradient—addresses a key limitation of existing HCM therapies and expands the addressable patient population beyond specialized centers of excellence. With Phase 3 initiation targeted for Q4 2026 and the upfront Servier proceeds fully funding development, EDG-7500 is on a clear path to potential approval, representing a significant near-term value inflection point that the market may not be fully pricing in given the recent focus on the muscular dystrophy divestiture.
Edgewise's cardiovascular pipeline extends beyond EDG-7500 to include EDG-15400, a novel cardiac sarcomere modulator targeting HFpEF—a large and growing indication with significant unmet need and limited effective therapies. The company expects to initiate a Phase 2 trial of EDG-15400 in HFpEF in the second half of 2026, supported by ongoing Phase 1 healthy adult data expected in H1 2026. HFpEF affects over 6 million people in the U.S. alone, with prevalence rising due to aging populations and comorbidities like hypertension and diabetes, yet no disease-modifying therapies are currently approved. EDG-15400's mechanism—selectively modulating cardiac sarcomere function to improve diastolic relaxation without impairing systolic function—aligns with the pathophysiology of HFpEF and mirrors the differentiated safety approach seen with EDG-7500. The market may be overlooking the optionality and long-term value of this second cardiovascular asset, which, combined with EDG-7500, creates a dual-engine growth platform in cardiovascular therapeutics with minimal overlap in clinical development risk and substantial synergies in manufacturing, regulatory strategy, and commercial infrastructure.
Edgewise Therapeutics is positioned for transformative value creation through the Servier transaction, which provides $1.55 billion in upfront cash, significantly de-risking the company's near-term operations while unlocking its cardiovascular pipeline. This transaction eliminates the financial burden of muscular dystrophy program development, allowing Edgewise to redirect capital and focus entirely toward EDG-7500 for hypertrophic cardiomyopathy (HCM) and EDG-15400 for heart failure with preserved ejection fraction (HFpEF). With $1.55 billion in upfront proceeds combined with its existing cash balance of approximately $500 million as of Q1 2026, Edgewise now holds over $2 billion in liquidity, which management explicitly states will fully fund EDG-7500 development through potential approval. This financial strength removes a critical overhang that has historically weighed on biotech valuations—particularly the need for dilutive financing—while enabling aggressive investment in Phase 3 trials without compromise. The market may be underestimating how this structural shift transforms Edgewise from a dual-program clinical-stage company with high cash burn into a pure-play cardiovascular innovator with fortress-like balance sheet strength, potentially attracting a premium valuation multiple as investors re-rate the company on its de-risked, focused pipeline.
The near-term catalysts for EDG-7500 in HCM are substantially derisked by compelling interim safety and efficacy data, with the CIRRUS-HCM Part D 12-week readout expected in Q2 2026 poised to confirm a best-in-class profile. Unlike cardiac myosin inhibitors (CMIs), which carry inherent risks of systolic dysfunction and heart failure due to their mechanism of action, EDG-7500 has consistently demonstrated no clinically meaningful reductions in left ventricular ejection fraction (LVEF) or events of LVEF falling below 50% across all trial phases, including Part D interim safety updates. This differentiated safety profile—preserving systolic function while improving diastolic markers like NT-proBNP, KCCQ scores, and LVOT gradient—addresses a key limitation of existing HCM therapies and expands the addressable patient population beyond specialized centers of excellence. With Phase 3 initiation targeted for Q4 2026 and the upfront Servier proceeds fully funding development, EDG-7500 is on a clear path to potential approval, representing a significant near-term value inflection point that the market may not be fully pricing in given the recent focus on the muscular dystrophy divestiture.
Edgewise's cardiovascular pipeline extends beyond EDG-7500 to include EDG-15400, a novel cardiac sarcomere modulator targeting HFpEF—a large and growing indication with significant unmet need and limited effective therapies. The company expects to initiate a Phase 2 trial of EDG-15400 in HFpEF in the second half of 2026, supported by ongoing Phase 1 healthy adult data expected in H1 2026. HFpEF affects over 6 million people in the U.S. alone, with prevalence rising due to aging populations and comorbidities like hypertension and diabetes, yet no disease-modifying therapies are currently approved. EDG-15400's mechanism—selectively modulating cardiac sarcomere function to improve diastolic relaxation without impairing systolic function—aligns with the pathophysiology of HFpEF and mirrors the differentiated safety approach seen with EDG-7500. The market may be overlooking the optionality and long-term value of this second cardiovascular asset, which, combined with EDG-7500, creates a dual-engine growth platform in cardiovascular therapeutics with minimal overlap in clinical development risk and substantial synergies in manufacturing, regulatory strategy, and commercial infrastructure.
Despite the optimistic narrative around the Servier transaction, Edgewise Therapeutics faces substantial execution risk in its pivot to a pure-play cardiovascular company, particularly given its limited track record in bringing any product to market and the high failure rates inherent in Phase 3 cardiovascular trials. The company has never generated revenue, and its lead cardiovascular candidate, EDG-7500, remains in Phase 2 development with no Phase 3 data yet available—making the assumption that Servier's upfront proceeds will "fully fund development through potential approval" highly speculative and contingent on success in costly, lengthy pivotal trials. Cardiovascular drug development is notoriously capital-intensive, with Phase 3 trials often requiring thousands of patients and hundreds of millions in expenses; even with $2 billion in liquidity, unforeseen delays, efficacy shortfalls, or safety signals could rapidly erode this runway. Moreover, the market may be overestimating the strategic clarity of the transaction, as Edgewise now relies entirely on the success of two early-stage cardiac programs (EDG-7500 and EDG-15400) in indications with crowded competitive landscapes, including entrenched players and emerging therapies like cardiac myosin inhibitors for HCM and SGLT2 inhibitors for HFpEF, which could diminish EDG-7500's differentiation if its clinical advantages fail to translate into meaningful real-world outcomes.
The long-term value of sevasemten, while monetized through the Servier deal, introduces contingent consideration risk that may not be fully realizable, and Edgewise's future success remains indirectly tied to the muscular dystrophy business it just divested. Although Edgewise retains no direct ownership of sevasemten post-transaction, the deal includes up to $1.1 billion in milestone payments contingent on regulatory and commercial achievements by Servier—milestones that are far from guaranteed given the competitive landscape in Duchenne (where approved gene therapies like Elevidys already exist) and the ultra-rare nature of Becker (with only ~12,000 affected individuals across the U.S., EU-5, and Japan). If Servier fails to meet these milestones due to clinical setbacks, regulatory delays, or commercial adoption challenges, Edgewise will not receive the full potential proceeds, undermining the financial strength narrative. Furthermore, by divesting its muscular dystrophy business, Edgewise has eliminated any potential upside from sevasemten's success beyond the agreed milestones, capping its upside while retaining exposure to downside risks if Servier's development falters and reflects poorly on the asset's credibility—a nuance the market may be overlooking in its enthusiasm for the upfront cash.
Edgewise's cardiovascular pipeline, while promising, faces significant competitive and regulatory headwinds that could limit commercial potential even if technical success is achieved. EDG-7500 enters an HCM market where therapeutic innovation is accelerating, with multiple cardiac myosin inhibitors (e.g., aficamten, danicamtide) in late-stage development and established off-label use of beta-blockers and calcium channel blockers creating a high bar for differentiation. Although EDG-7500's preservation of LVEF is a theoretical advantage, the market has not yet validated whether this translates to superior clinical outcomes, reduced hospitalization, or improved survival—endpoints that payers and regulators will demand for premium pricing and broad adoption. Similarly, EDG-15400 targets HFpEF, an indication where recent trials of novel agents (including SGLT2 inhibitors and finerenone) have set a high efficacy and safety benchmark, making it difficult for a new mechanism to demonstrate incremental value without large, expensive outcomes trials. The company's reliance on biomarker-guided dose optimization in CIRRUS-HCM Part D, while scientifically sound, may not guarantee Phase 3 success if surrogate endpoints like NT-proBNP or LVOT-G fail to correlate with hard clinical benefits in larger, diverse populations—a risk amplified by the small patient enrollment in early Part D cohorts (only 20 completing 12 weeks as of Dec 2025) and the inherent uncertainty in translating Phase 2 signals to Phase 3 results.
Despite the optimistic narrative around the Servier transaction, Edgewise Therapeutics faces substantial execution risk in its pivot to a pure-play cardiovascular company, particularly given its limited track record in bringing any product to market and the high failure rates inherent in Phase 3 cardiovascular trials. The company has never generated revenue, and its lead cardiovascular candidate, EDG-7500, remains in Phase 2 development with no Phase 3 data yet available—making the assumption that Servier's upfront proceeds will "fully fund development through potential approval" highly speculative and contingent on success in costly, lengthy pivotal trials. Cardiovascular drug development is notoriously capital-intensive, with Phase 3 trials often requiring thousands of patients and hundreds of millions in expenses; even with $2 billion in liquidity, unforeseen delays, efficacy shortfalls, or safety signals could rapidly erode this runway. Moreover, the market may be overestimating the strategic clarity of the transaction, as Edgewise now relies entirely on the success of two early-stage cardiac programs (EDG-7500 and EDG-15400) in indications with crowded competitive landscapes, including entrenched players and emerging therapies like cardiac myosin inhibitors for HCM and SGLT2 inhibitors for HFpEF, which could diminish EDG-7500's differentiation if its clinical advantages fail to translate into meaningful real-world outcomes.
The long-term value of sevasemten, while monetized through the Servier deal, introduces contingent consideration risk that may not be fully realizable, and Edgewise's future success remains indirectly tied to the muscular dystrophy business it just divested. Although Edgewise retains no direct ownership of sevasemten post-transaction, the deal includes up to $1.1 billion in milestone payments contingent on regulatory and commercial achievements by Servier—milestones that are far from guaranteed given the competitive landscape in Duchenne (where approved gene therapies like Elevidys already exist) and the ultra-rare nature of Becker (with only ~12,000 affected individuals across the U.S., EU-5, and Japan). If Servier fails to meet these milestones due to clinical setbacks, regulatory delays, or commercial adoption challenges, Edgewise will not receive the full potential proceeds, undermining the financial strength narrative. Furthermore, by divesting its muscular dystrophy business, Edgewise has eliminated any potential upside from sevasemten's success beyond the agreed milestones, capping its upside while retaining exposure to downside risks if Servier's development falters and reflects poorly on the asset's credibility—a nuance the market may be overlooking in its enthusiasm for the upfront cash.
Edgewise's cardiovascular pipeline, while promising, faces significant competitive and regulatory headwinds that could limit commercial potential even if technical success is achieved. EDG-7500 enters an HCM market where therapeutic innovation is accelerating, with multiple cardiac myosin inhibitors (e.g., aficamten, danicamtide) in late-stage development and established off-label use of beta-blockers and calcium channel blockers creating a high bar for differentiation. Although EDG-7500's preservation of LVEF is a theoretical advantage, the market has not yet validated whether this translates to superior clinical outcomes, reduced hospitalization, or improved survival—endpoints that payers and regulators will demand for premium pricing and broad adoption. Similarly, EDG-15400 targets HFpEF, an indication where recent trials of novel agents (including SGLT2 inhibitors and finerenone) have set a high efficacy and safety benchmark, making it difficult for a new mechanism to demonstrate incremental value without large, expensive outcomes trials. The company's reliance on biomarker-guided dose optimization in CIRRUS-HCM Part D, while scientifically sound, may not guarantee Phase 3 success if surrogate endpoints like NT-proBNP or LVOT-G fail to correlate with hard clinical benefits in larger, diverse populations—a risk amplified by the small patient enrollment in early Part D cohorts (only 20 completing 12 weeks as of Dec 2025) and the inherent uncertainty in translating Phase 2 signals to Phase 3 results.